Flexion Therapeutics, Inc. (FLXN): Price and Financial Metrics

Flexion Therapeutics, Inc. (FLXN): $9.12

0.02 (-0.22%)

POWR Rating

Component Grades








Add FLXN to Watchlist
Sign Up

FLXN Price/Volume Stats

Current price $9.12 52-week high $13.66
Prev. close $9.14 52-week low $4.30
Day low $9.12 Volume 18,723,200
Day high $9.23 Avg. volume 1,177,479
50-day MA $7.97 Dividend yield N/A
200-day MA $8.28 Market Cap 458.93M

FLXN Stock Price Chart Interactive Chart >

Flexion Therapeutics, Inc. (FLXN) Company Bio

Flexion Therapeutics focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. The company was founded in 2007 and is based in Burlington, Massachusetts.

FLXN Latest News Stream

Event/Time News Detail
Loading, please wait...

FLXN Latest Social Stream

Loading social stream, please wait...

View Full FLXN Social Stream

Latest FLXN News From Around the Web

Below are the latest news stories about Flexion Therapeutics Inc that investors may wish to consider to help them evaluate FLXN as an investment opportunity.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ECHO, ACBI, HRC, FLXN; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:Echo Global Logistics, Inc. (NASDAQ:ECHO)concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to funds managed by The Jordan Company, L.

Yahoo | November 4, 2021

Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark

Pacira's (PCRX) earnings beat estimates in the third quarter of 2021 while revenues miss the same. Its flagship product Exparel's sales rise year over year.

Yahoo | November 3, 2021

Pacira BioSciences, inc (PCRX) Q3 2021 Earnings Call Transcript

Joining me as speakers on today's call are Dave Stack, Chairman and Chief Executive Officer; and Charlie Reinhart, Chief Financial Officer. Before we begin, let me remind you that today's call will include forward-looking statements based on current expectations, including those related to the potential transaction between Pacira and Flexion Therapeutics.

Yahoo | November 3, 2021

FLEXION THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion Therapeutics, Inc. - FLXN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Flexion Therapeutics, Inc. (NasdaqGM: FLXN) to Pacira BioSciences, Inc. (NasdaqGS: PCRX). Under the terms of the proposed transaction, shareholders of Flexion will receive only $8.50 in cash and one non-tradable contingent value right (CVR) worth up to $8.00 per share in cash (assuming certain conditions are met) for each share of Flexion that

Yahoo | November 2, 2021

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ACBI, GTS, ADTN, COLB, DSPG, FLXN; Shareholders are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Yahoo | November 2, 2021

Read More 'FLXN' Stories Here

FLXN Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year 11.76%
5-year -15.40%
2023 N/A
2022 N/A
2021 0.00%
2020 -44.25%
2019 82.86%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!